Limna - Lausanne Integrative Metabolism Nutrition Alliance

François Jornayvaz

Geneva University Hospitals - University of Geneva

Our lab is mainly focused on the link between nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) and insulin resistance, which represents a key step in the development of type 2 diabetes. The topic is of importance and clinically relevant since type 2 diabetes is projected to increase and affect 592 million people worldwide by 2035. NAFLD/NASH is a very important disease and now represents the most frequent chronic liver disease worldwide. It is estimated to affect up to 60 to 70% of people with type 2 diabetes. Moreover, NAFLD represents the hepatic manifestation of the metabolic syndrome and as such represents a cardiovascular risk factor. The aims of the lab are therefore to: identify patients with NAFLD; identify which patients will present progression of their hepatic disease; and find therapeutic targets to prevent and heal NAFLD/NASH. To these ends, we use a translational approach using cell cultures, in vivo animal models and humans.


  • Insulin resistance
  • Inflammation
  • Type 2 diabetes
  • Obesity


Dr François Jornayvaz, MD

Head of the Diabetes Unit

Geneva University Hospital


Rue Gabrielle-Perret-Gentil 4, CH-1211 Genève 14, Switzerland